NewAmsterdam Pharma N.V. (NAMS)
22.54
-0.87 (-3.72%)
At close: Mar 26, 2025, 3:59 PM
24.02
6.55%
Pre-market: Mar 27, 2025, 05:03 AM EDT
-3.72% (1D)
| Bid | 23.09 |
| Market Cap | 2.48B |
| Revenue (ttm) | 52.73M |
| Net Income (ttm) | -270.16M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -8.8 |
| Forward PE | -12.31 |
| Analyst | Buy |
| Ask | 28 |
| Volume | 986,105 |
| Avg. Volume (20D) | 867,249 |
| Open | 23.21 |
| Previous Close | 23.41 |
| Day's Range | 22.06 - 23.34 |
| 52-Week Range | 15.19 - 27.29 |
| Beta | -0.04 |
About NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMS
Analyst Forecast
According to 6 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 86.34% from the latest price.
Stock Forecasts4 weeks ago
+6.09%
NewAmsterdam Pharma shares are trading higher afte...
Unlock content with
Pro Subscription
4 weeks ago
+10.23%
NewAmsterdam Pharma shares are trading higher after the company reported better-than-expected FY24 sales results.
